Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models
Open accessThe DOI matches its Crossref record; 164 of the 168 references it cites were found in a registry or an index.
Abstract
Drug-induced liver injury (DILI) is a challenging clinical event in medicine, particularly because of its ability to present with a variety of phenotypes including that of autoimmune hepatitis or other immune mediated liver injuries. Limited diagnostic and therapeutic tools are available, mostly because its pathogenesis has remained poorly understood for decades. The recent scientific and technological advancements in genomics and immunology are paving the way for a better understanding of the molecular aspects of DILI. This review provides an updated overview of the genetic predisposition and immunological mechanisms behind the pathogenesis of DILI and presents the state-of-the-art experimental models to study DILI at the pre-clinical level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“reinforcing their well-established role in modeling immune–driven liver damage (Chakraborty et al., 2015; Gerussi et al., 2021).”
From A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics (2026) · cites this paper as Gerussi et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immune-mediated DILI is related to the pharmacodynamic properties of the drug rather than direct or idiosyncratic liver injury, is not dose-related, but partially predictable, and arises when the host immune system leads to liver injury following medication administration.[3,5]”
From Drug-induced liver injury: Diagnosis, management and the role of liver transplantation (2025) · cites this paper as [5]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“Immune checkpoints are physiological molecules fundamental in the negative control of immune response, acting as minimizer or even suppressor of immune activity, in order to avoid potential tissue damage from aberrant inflammatory response [103].”
BackgroundJaneway, C. A., & Medzhitov, R. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.083001.084359 · Cited by 8,394
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Neutrophil recruitment and function in health and inflammation
Kolaczkowska, E., & Kubes, P. (2013) · Nature Reviews Immunology · doi:10.1038/nri3399 · Cited by 5,472 · cited 1×
“A proto-typical example of drug-induced sterile inflammation is that occurring in APAP-DILI; in this scenario, inflammation can be inhibited by neutralization of HMGB1, one of the DAMPs released by hepatocytes [14,21,27].”
BackgroundRittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675
Macrophages in Tissue Repair, Regeneration, and Fibrosis
Wynn, T. A., & Vannella, K. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.015 · Cited by 4,481
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154 · cited 1×
“inducing the persistent activation of immune response [105].”
BackgroundSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
A global overview of pleiotropy and genetic architecture in complex traits
Watanabe, K., Stringer, S., Frei, O., Umićević Mirkov, M., de Leeuw, C., Polderman, T. J. C., van der Sluis, S., Andreassen, O. A., Neale, B. M., & Posthuma, D. (2019) · Nature Genetics · doi:10.1038/s41588-019-0481-0 · Cited by 1,332 · cited 1×
“The high degree of variance which characterizes iDILI speaks for a polygenic genetic architecture, where several risk variants are interconnected in a network where each provides a small effect size [8].”
BackgroundEASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276 · cited 4×
“Drug-induced Liver Injury (DILI) is defined by the presence of some degree of liver injury, commonly detected by the rise of liver-related enzymes in the blood, which can be causally related to a specific drug [1].”
BackgroundInfluentialSelf-citationHamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3397 · Cited by 1,180
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A., Routier, E., Lambotte, O., Ladurie, F. L., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,102
Lesokhin, A. M., Ansell, S. M., Armand, P., Scott, E. C., Halwani, A., Gutierrez, M., Millenson, M. M., Cohen, A. D., Schuster, S. J., Lebovic, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.9789 · Cited by 1,001
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Self-citationBhatia, S. N., Balis, U. J., Yarmush, M. L., & Toner, M. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.14.1883 · Cited by 890
Neutrophil Recruitment by Human IL-17 Via C-X-C Chemokine Release in the Airways
Laan, M., Cui, Z.-H., Hoshino, H., Lötvall, J., Sjöstrand, M., Gruenert, D. C., Skoogh, B.-E., & Lindén, A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.4.2347 · Cited by 880
NKT cells: facts, functions and fallacies
Godfrey, D. I., Hammond, K. J. L., Poulton, L. D., Smyth, M. J., & Baxter, A. G. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01735-7 · Cited by 858 · cited 1×
“Natural Killer T (NKT) cells are abundant liver-resident innate lymphocytes whose role in liver inflammation has been demonstrated in several diseases [24,39,40].”
BackgroundBell, C. C., Hendriks, D. F. G., Moro, S. M. L., Ellis, E., Walsh, J., Renblom, A., Fredriksson Puigvert, L., Dankers, A. C. A., Jacobs, F., Snoeys, J., et al. (2016) · Scientific Reports · doi:10.1038/srep25187 · Cited by 739 · cited 1×
“Interestingly, this model can predict DILI of the chemical fialuridine, which goes undetected using previous in vitro systems [142].”
BackgroundStepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., & Aleo, M. D. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200168d · Cited by 698 · cited 1×
“Specific chemical substructures or motifs are statistically associated with elevated risk of toxicity by commercial software [119].”
BackgroundImmune self-reactivity triggered by drug-modified HLA-peptide repertoire
Illing, P. T., Vivian, J. P., Dudek, N. L., Kostenko, L., Chen, Z., Bharadwaj, M., Miles, J. J., Kjer-Nielsen, L., Gras, S., Williamson, N. A., et al. (2012) · Nature · doi:10.1038/nature11147 · Cited by 696 · cited 1×
“An alternative rare possibility is that the drug changes the HLA-binding site for the antigenic peptide, leading to a change in the repertoire of presented peptides [73].”
BackgroundGuillouzo, A., Corlu, A., Aninat, C., Glaise, D., Morel, F., & Guguen-Guillouzo, C. (2007) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.12.003 · Cited by 675 · cited 1×
“HepaRG can proliferate and differentiate to form colonies surrounded by epithelial cells expressing metabolizing enzymes and drug transporters [127,128].”
BackgroundSterile inflammation in the liver
Kubes, P., & Mehal, W. Z. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.09.008 · Cited by 666 · cited 1×
“KCs are activated by DAMPs binding to TLRs and purigenic receptors [29].”
BackgroundDrug-induced liver injury—types and phenotypes
Hoofnagle, J. H., & Björnsson, E. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1816149 · Cited by 652 · cited 10×
“More recently, a third type of DILI, the indirect type, has been proposed: in terms of frequency, relation to the dose, predictability and reproducibility, it can be placed halfway between the other two types, has a slower onset (typically months) and it is mechanistically related to the pharmacodynamic properties of…”
BackgroundInfluentialAcetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome
Imaeda, A. B., Watanabe, A., Sohail, M. A., Mahmood, S., Mohamadnejad, M., Sutterwala, F. S., Flavell, R. A., & Mehal, W. Z. (2009) · Journal of Clinical Investigation · doi:10.1172/jci35958 · Cited by 607 · cited 1×
“The activation of KCs results in the production of proIL-1β and proIL-18, that are cleaved intracellularly by caspase-1, and released as mature IL-1β and IL-18, respectively [30].”
BackgroundWestin, J. R., Chu, F., Zhang, M., Fayad, L. E., Kwak, L. W., Fowler, N., Romaguera, J., Hagemeister, F., Fanale, M., Samaniego, F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70551-5 · Cited by 529
Sallusto, F., & Lanzavecchia, A. (2000) · Immunological Reviews · doi:10.1034/j.1600-065x.2000.17717.x · Cited by 523 · cited 3×
“In a typical immune response, for example upon infection, DCs activated in the infected tissue up-take and process pathogen-derived antigens, up-regulate co-stimulatory molecules (e.g., CD80 and CD86, two B7 family members) and the chemokine receptor CCR7, and migrate as “maturing” APCs to draining lymph nodes (LNs) v…”
BackgroundInfluentialZigmond, E., Samia-Grinberg, S., Pasmanik-Chor, M., Brazowski, E., Shibolet, O., Halpern, Z., & Varol, C. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400574 · Cited by 480
Jaeschke, H. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00568.2005 · Cited by 475
Nayak, L., Iwamoto, F. M., LaCasce, A., Mukundan, S., Roemer, M. G. M., Chapuy, B., Armand, P., Rodig, S. J., & Shipp, M. A. (2017) · Blood · doi:10.1182/blood-2017-01-764209 · Cited by 453
Mechanisms of neutrophil-induced parenchymal cell injury
Jaeschke, H., & Smith, C. W. (1997) · Journal of Leukocyte Biology · doi:10.1002/jlb.61.6.647 · Cited by 445 · cited 1×
“β2 integrin-mediated interactions are also required for neutrophil/hepatocyte contact, that leads to the production of reactive oxygen species (ROS) by neutrophils, and hepatocytes damage and death [49,50].”
BackgroundDrug-induced autoimmune hepatitis: clinical characteristics and prognosis
Björnsson, E., Talwalkar, J., Treeprasertsuk, S., Kamath, P. S., Takahashi, N., Sanderson, S., Neuhauser, M., & Lindor, K. (2010) · Hepatology · doi:10.1002/hep.23588 · Cited by 436 · cited 4×
“Drug-induced AIH is reported to represent around 9% of all AIH cases [5] and its disease course is thought to be more favorable, with a higher probability of withdrawing immunosuppressive therapy without relapses [5].”
BackgroundInfluentialPembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
Ding, W., LaPlant, B. R., Call, T. G., Parikh, S. A., Leis, J. F., He, R., Shanafelt, T. D., Sinha, S., Le-Rademacher, J., Feldman, A. L., et al. (2017) · Blood · doi:10.1182/blood-2017-02-765685 · Cited by 407
Eigentler, T. K., Hassel, J. C., Berking, C., Aberle, J., Bachmann, O., Grünwald, V., Kähler, K. C., Loquai, C., Reinmuth, N., Steins, M., et al. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.003 · Cited by 406 · cited 1×
“Among the serious immune-related AEs, there are endocrinopathies, pneumonitis, colitis and hepatitis [99,100].”
BackgroundEndocrine Side Effects Induced by Immune Checkpoint Inhibitors
Corsello, S. M., Barnabei, A., Marchetti, P., De Vecchis, L., Salvatori, R., & Torino, F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4075 · Cited by 403 · cited 1×
“Among the serious immune-related AEs, there are endocrinopathies, pneumonitis, colitis and hepatitis [99,100].”
BackgroundHolt, M. P., Cheng, L., & Ju, C. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0308173 · Cited by 399 · cited 2×
“The contribution of different cell types to inflammation and tissue repair, and the underlying molecular mechanisms, have been further investigated in mouse models of DILI [27,28].”
BackgroundLammert, C., Einarsson, S., Saha, C., Niklasson, A., Bjornsson, E., & Chalasani, N. (2008) · Hepatology · doi:10.1002/hep.22272 · Cited by 389
Yang, W., Tao, Y., Wu, Y., Zhao, X., Ye, W., Zhao, D., Fu, L., Tian, C., Yang, J., He, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09046-8 · Cited by 367 · cited 5×
“For example, neutrophil depletion by anti-Ly6G antibody treatment resulted in reduced hepatocyte proliferation and increased liver necrosis in mouse APAP-DILI [55].”
BackgroundInfluentialChen, M., Borlak, J., & Tong, W. (2013) · Hepatology · doi:10.1002/hep.26208 · Cited by 348
Bradham, C. A., Plümpe, J., Manns, M. P., Brenner, D. A., & Trautwein, C. (1998) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1998.275.3.g387 · Cited by 340
Katarey, D., & Verma, S. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-6-s104 · Cited by 331
Role of Neutrophils in the Pathogenesis of Acute Inflammatory Liver Injury
Ramaiah, S. K., & Jaeschke, H. (2007) · Toxicologic Pathology · doi:10.1080/01926230701584163 · Cited by 328
Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury
Proctor, W. R., Foster, A. J., Vogt, J., Summers, C., Middleton, B., Pilling, M. A., Shienson, D., Kijanska, M., Ströbel, S., Kelm, J. M., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-2002-1 · Cited by 328
Bell, C. C., Dankers, A. C. A., Lauschke, V. M., Sison-Young, R., Jenkins, R., Rowe, C., Goldring, C. E., Park, K., Regan, S. L., Walker, T., et al. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfx289 · Cited by 327 · cited 1×
“Another significant example is derived from Bell and colleagues, who generated spheroids from primary human cryopreserved hepatocytes and non-parenchymal cells and compared them to the 2D cell models [141].”
BackgroundMossanen, J. C., Krenkel, O., Ergen, C., Govaere, O., Liepelt, A., Puengel, T., Heymann, F., Kalthoff, S., Lefebvre, E., Eulberg, D., et al. (2016) · Hepatology · doi:10.1002/hep.28682 · Cited by 325 · cited 12×
“Recruitment and activation of effector T cells into the liver can result in liver damage via different mechanisms, including production of diverse proinflammatory (IFN-γ, IL-17, etc.) and pro-allergic (IL-4, IL-5, IL-13, etc.) cytokines by CD4+ T cells, and cytotoxicity via either exocytosis of perforin- and granzyme-…”
BackgroundInfluentialNeutrophil depletion protects against murine acetaminophen hepatotoxicity†‡
Liu, Z., Han, D., Gunawan, B., & Kaplowitz, N. (2006) · Hepatology · doi:10.1002/hep.21175 · Cited by 324 · cited 1×
“Neutropenia induced by the use of anti-neutrophil antibodies before APAP overdose can reduce hepatotoxicity [152], but an important role seems also to be played by Kupffer cell activation, since a depletion of this liver component significantly reduced liver damage in APAP overdose in mice [153].”
BackgroundNatural killer cells in liver disease
Tian, Z., Chen, Y., & Gao, B. (2013) · Hepatology · doi:10.1002/hep.26115 · Cited by 290 · cited 1×
“Natural Killer T (NKT) cells are abundant liver-resident innate lymphocytes whose role in liver inflammation has been demonstrated in several diseases [24,39,40].”
BackgroundDrug induced liver injury: an update
Garcia-Cortes, M., Robles-Diaz, M., Stephens, C., Ortega-Alonso, A., Lucena, M. I., & Andrade, R. J. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02885-1 · Cited by 286 · cited 2×
“Nonetheless, the presence of this third variant is still a matter of debate in the scientific community [4].”
BackgroundSelf-citationPluripotent stem cell-derived hepatocyte-like cells
Schwartz, R. E., Fleming, H. E., Khetani, S. R., & Bhatia, S. N. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.01.003 · Cited by 282 · cited 1×
“The use of human induced pluripotent stem cell for derivation of hepatocyte-like cells represents another option despite remaining suboptimal, because cells are not fully metabolically competent and show very low levels of activity of the metabolizing enzymes [129,130].”
BackgroundAntoniades, C. G., Quaglia, A., Taams, L. S., Mitry, R. R., Hussain, M., Abeles, R., Possamai, L. A., Bruce, M., McPhail, M., Starling, C., et al. (2012) · Hepatology · doi:10.1002/hep.25657 · Cited by 281 · cited 2×
“When stimulated in vitro in the presence of APCs, amoxicillin-specific CD4+ T cells were polyfunctional and secreted IFN-γ, IL-10, perforin and/or IL-17/IL-22 [61,74], while clavulanic acid-specific CD4+ T cells mostly produced IFN-γ [61].”
BackgroundZen, Y., & Yeh, M. M. (2018) · Modern Pathology · doi:10.1038/s41379-018-0013-y · Cited by 266 · cited 1×
“Plasma cell infiltrates are not typical of ICI-induced hepatitis [106,108], in contrast to classical AIH, where they constitute the predominant cell type together with lymphocytes and accumulate in periportal areas [109].”
ResultYamada, Y., Webber, E. M., Kirillova, I., Peschon, J. J., & Fausto, N. (1998) · Hepatology · doi:10.1002/hep.510280410 · Cited by 264 · cited 1×
“Additional studies have demonstrated that TNF-α is also a key factor for hepatocyte proliferation during liver regeneration in different conditions [35,36], including a mouse model of APAP-DILI [37].”
BackgroundMonshi, M. M., Faulkner, L., Gibson, A., Jenkins, R. E., Farrell, J., Earnshaw, C. J., Alfirevic, A., Cederbrant, K., Daly, A. K., French, N., et al. (2013) · Hepatology · doi:10.1002/hep.26077 · Cited by 258 · cited 1×
“Clones were specific for floxacillin, but could also react to other β-lactam antibiotics, but not to abacavir [75].”
BackgroundWeaver, R. J., Blomme, E. A., Chadwick, A. E., Copple, I. M., Gerets, H. H. J., Goldring, C. E., Guillouzo, A., Hewitt, P. G., Ingelman-Sundberg, M., Jensen, K. G., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0048-x · Cited by 249 · cited 3×
“The complex network of interactions among genetic, environmental, immune and metabolic factors behind DILI implies that its pathophysiological mechanisms cannot be recapitulated in a single study model [116].”
BackgroundHuman liver cell spheroids in extended perfusion bioreactor culture for repeated-dose drug testing
Tostões, R. M., Leite, S. B., Serra, M., Jensen, J., Björquist, P., Carrondo, M. J. T., Brito, C., & Alves, P. M. (2012) · Hepatology · doi:10.1002/hep.24760 · Cited by 246 · cited 1×
“In some cases, even vascular- and bile canaliculi-like structures have been observed [145,146].”
BackgroundCardiotoxicity of immune checkpoint inhibitors
Varricchi, G., Galdiero, M. R., Marone, G., Criscuolo, G., Triassi, M., Bonaduce, D., Marone, G., & Tocchetti, C. G. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000247 · Cited by 246
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents
Weber, J. S., Postow, M., Lao, C. D., & Schadendorf, D. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0055 · Cited by 237 · cited 1×
“A higher susceptibility to develop an ICI-induced liver toxicity has been observed in patients receiving immunotherapy combinations [101,102].”
BackgroundIpilimumab associated hepatitis: imaging and clinicopathologic findings
Kim, K. W., Ramaiya, N. H., Krajewski, K. M., Jagannathan, J. P., Tirumani, S. H., Srivastava, A., & Ibrahim, N. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9939-6 · Cited by 235 · cited 1×
“A higher susceptibility to develop an ICI-induced liver toxicity has been observed in patients receiving immunotherapy combinations [101,102].”
BackgroundTumor necrosis factor α, but not Fas, mediates hepatocellular apoptosis in the murine ischemic liver
Rüdiger, H. A., & Clavien, P. (2002) · Gastroenterology · doi:10.1053/gast.2002.30304 · Cited by 233 · cited 1×
“Furthermore, KCs can produce tumor necrosis factor alpha (TNF-α), which can kill hepatocytes and recruit inflammatory leukocytes in several types of liver injury [33,34] (Figure 1A).”
BackgroundPTPN22: the archetypal non-HLA autoimmunity gene
Stanford, S. M., & Bottini, N. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.109 · Cited by 227 · cited 6×
“The same SNP has been associated to increased risk of type 1 diabetes mellitus, rheumatoid arthritis, systemic lupus erythematosus, and several other autoimmune conditions [13]; it is considered one of the most important non-HLA allele for rheumatoid arthritis and juvenile idiopathic arthritis susceptibility [13].”
BackgroundInfluentialA human liver microphysiology platform for investigating physiology, drug safety, and disease models
Vernetti, L. A., Senutovitch, N., Boltz, R., DeBiasio, R., Ying Shun, T., Gough, A., & Taylor, D. L. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370215592121 · Cited by 226 · cited 1×
“) has to be used for the development of increasingly efficient “3D microphysiology systems” (miniaturized functional liver units constructed with multiple cell types under a variety of mechanical and biochemical cues) for the study of DILI [116,147,148].”
BackgroundMerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure
Triantafyllou, E., Pop, O. T., Possamai, L. A., Wilhelm, A., Liaskou, E., Singanayagam, A., Bernsmeier, C., Khamri, W., Petts, G., Dargue, R., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313615 · Cited by 226 · cited 3×
“The depicted mechanisms are supported by examination of liver infiltrates from patients with floxacillin-induced DILI [58], and by in vitro studies of effector functions by CD4+ and CD8+ T cell clones obtained from patients with DILI induced by amoxicillin, clavulanic acid and tolvaptan [59,72,74].”
BackgroundXu, J. J., Diaz, D., & O’Brien, P. J. (2004) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2004.09.011 · Cited by 224 · cited 2×
“In addition, the predictive power is higher when the assays target early steps in the process of cell injury, before cell death stages [122].”
BackgroundDynamics and genomic landscape of CD8+ T cells undergoing hepatic priming
Bénéchet, A. P., De Simone, G., Di Lucia, P., Cilenti, F., Barbiera, G., Le Bert, N., Fumagalli, V., Lusito, E., Moalli, F., Bianchessi, V., et al. (2019) · Nature · doi:10.1038/s41586-019-1620-6 · Cited by 222 · cited 1×
“It remains to be determined whether cells other than liver DCs play a role in T cell priming in DILI, for example LN macrophages, or liver KCs, and endothelial cells, as shown in other conditions [64,65].”
BackgroundNicoletti, P., Aithal, G. P., Bjornsson, E. S., Andrade, R. J., Sawle, A., Arrese, M., Barnhart, H. X., Bondon-Guitton, E., Hayashi, P. H., Bessone, F., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.12.016 · Cited by 221 · cited 3×
“The drug itself or its metabolites form adducts that bind HLA molecules and consequently activate T-cell response [10].”
BackgroundSelf-citationMechanism of isoniazid‐induced hepatotoxicity: then and now
Metushi, I., Uetrecht, J., & Phillips, E. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12885 · Cited by 217 · cited 2×
“However, evolution into overt autoimmune hepatitis might occur in the presence of additional underlying factors [1,80].”
BackgroundWu, J., Meng, Z., Jiang, M., Zhang, E., Trippler, M., Broering, R., Bucchi, A., Krux, F., Dittmer, U., Yang, D., et al. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03179.x · Cited by 214 · cited 2×
“, in the presence of Interferons and/or TLR ligands, DCs up-regulate MHC-I and -II molecules, while KCs and liver endothelial sinusoidal cells become MHC-II+ [68].”
BackgroundA microfluidic hepatic coculture platform for cell-based drug metabolism studies
Novik, E., Maguire, T. J., Chao, P., Cheng, K. C., & Yarmush, M. L. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.11.010 · Cited by 212 · cited 1×
“Additionally, an environment that reflects both the in vivo organ scaffolds (such as extracellular matrix) and mechanical signals (like fluid flow) may drastically improve cited models [136,137].”
BackgroundNeutrophils: a cornerstone of liver ischemia and reperfusion injury
Oliveira, T. H. C. D., Marques, P. E., Proost, P., & Teixeira, M. M. M. (2018) · Laboratory Investigation · doi:10.1038/labinvest.2017.90 · Cited by 212
Macrophage activation and skeletal muscle healing following traumatic injury
Novak, M. L., Weinheimer‐Haus, E. M., & Koh, T. J. (2014) · The Journal of Pathology · doi:10.1002/path.4301 · Cited by 210
Use of Micropatterned Cocultures to Detect Compounds That Cause Drug-Induced Liver Injury in Humans
Khetani, S. R., Kanchagar, C., Ukairo, O., Krzyzewski, S., Moore, A., Shi, J., Aoyama, S., Aleo, M., & Will, Y. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kfs326 · Cited by 208
Beckwitt, C. H., Clark, A. M., Wheeler, S., Taylor, D. L., Stolz, D. B., Griffith, L., & Wells, A. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.12.023 · Cited by 208
Drug‐induced liver injury: Advances in mechanistic understanding that will inform risk management
Mosedale, M., & Watkins, P. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.564 · Cited by 203 · cited 1×
“Indeed, innate immunity can be activated by damage-associated molecular patterns (DAMPs) released by drug-injured hepatocytes, resulting in inflammation in the absence of infectious agents, so-called sterile inflammation [16,17] (for definition of DAMPs and a brief outline on inflammation, see Box 1).”
BackgroundSelzner, N., Selzner, M., Odermatt, B., Tian, Y., van Rooijen, N., & Clavien, P. (2003) · Gastroenterology · doi:10.1053/gast.2003.50098 · Cited by 201 · cited 2×
“Nevertheless, these cells can also contribute to liver regeneration and repair [36,54].”
BackgroundBell, C. C., Lauschke, V. M., Vorrink, S. U., Palmgren, H., Duffin, R., Andersson, T. B., & Ingelman-Sundberg, M. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074369 · Cited by 201
Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
Badros, A., Hyjek, E., Ma, N., Lesokhin, A., Dogan, A., Rapoport, A. P., Kocoglu, M., Lederer, E., Philip, S., Milliron, T., et al. (2017) · Blood · doi:10.1182/blood-2017-03-775122 · Cited by 197
Osteopontin as a Mediator of NKT Cell Function in T Cell-Mediated Liver Diseases
Diao, H., Kon, S., Iwabuchi, K., Kimura, C., Morimoto, J., Ito, D., Segawa, T., Maeda, M., Hamuro, J., Nakayama, T., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.012 · Cited by 195
Ware, B. R., Berger, D. R., & Khetani, S. R. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv048 · Cited by 195 · cited 1×
“[132] used a micropatterned coculture, a model housing stem cell-derived hepatocytes and murine embryonic fibroblasts in collagen-treated tissue culture array.”
MethodFeatures of autoimmune hepatitis in patients with drug-induced liver injury
de Boer, Y. S., Kosinski, A. S., Urban, T. J., Zhao, Z., Long, N., Chalasani, N., Kleiner, D. E., & Hoofnagle, J. H. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.05.043 · Cited by 190
Wang, X., Sun, R., Wei, H., & Tian, Z. (2013) · Hepatology · doi:10.1002/hep.25982 · Cited by 189 · cited 1×
“γδ T cells can produce a huge amount of this cytokine, and γδ T cell depletion—but not that of NKT cells—in a APAP-DILI murine model was associated with reduced IL-17A level, decreased neutrophil infiltration and attenuated liver damage [44].”
BackgroundIpilimumab in patients with cancer and the management of dermatologic adverse events
Lacouture, M. E., Wolchok, J. D., Yosipovitch, G., Kähler, K. C., Busam, K. J., & Hauschild, A. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.02.035 · Cited by 187 · cited 1×
“In most patients, these AEs are mild and reversible [98].”
BackgroundVorrink, S. U., Zhou, Y., Ingelman-Sundberg, M., & Lauschke, V. M. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy058 · Cited by 187
Tissue specific synthetic ECM hydrogels for 3-D in vitro maintenance of hepatocyte function
Skardal, A., Smith, L., Bharadwaj, S., Atala, A., Soker, S., & Zhang, Y. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.03.034 · Cited by 183 · cited 1×
“Additionally, an environment that reflects both the in vivo organ scaffolds (such as extracellular matrix) and mechanical signals (like fluid flow) may drastically improve cited models [136,137].”
BackgroundOng, M. M. K., Latchoumycandane, C., & Boelsterli, U. A. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfl180 · Cited by 178 · cited 1×
“, reported that mice with a reduced level of Sod2 developed mild liver injury after administration of troglitazone [161], but these data were not further confirmed and, on the contrary, experiments performed in PD1−/− anti-CTLA4-treated mice do not seem to support such an important role of mitochondrial damage in iDIL…”
Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors
De Martin, E., Michot, J.-M., Rosmorduc, O., Guettier, C., & Samuel, D. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100170 · Cited by 175 · cited 10×
“PD-1 or PD-L1 inhibitors act by preventing the interaction between the ligand and its receptor, thus inducing the persistent activation of immune response [105].”
BackgroundResultInfluentialVorrink, S. U., Ullah, S., Schmidt, S., Nandania, J., Velagapudi, V., Beck, O., Ingelman‐Sundberg, M., & Lauschke, V. M. (2017) · The FASEB Journal · doi:10.1096/fj.201601375r · Cited by 172 · cited 1×
“In addition, the 3D spheroid model maintains the pharmacokinetic differences among donors, enabling the study of the human variability in DILI [143].”
BackgroundNeutrophil activation during acetaminophen hepatotoxicity and repair in mice and humans
Williams, C. D., Bajt, M. L., Sharpe, M. R., McGill, M. R., Farhood, A., & Jaeschke, H. (2014) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2014.01.004 · Cited by 170 · cited 1×
“Nevertheless, these cells can also contribute to liver regeneration and repair [36,54].”
BackgroundPenicilloyl peptides are recognized as T cell antigenic determinants in penicillin allergy
Padovan, E., Bauer, T., Tongio, M. M., Kalbacher, H., & Weltzien, H. U. (1997) · European Journal of Immunology · doi:10.1002/eji.1830270602 · Cited by 168 · cited 1×
“A well-known example of the “hapten” concept is the penicillin covalent binding to lysin residues, leading to presentation of penicilloyl peptides in the context of HLA to drug-specific T cells [69,71,72].”
BackgroundShaw, P. J., Hopfensperger, M. J., Ganey, P. E., & Roth, R. A. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm218 · Cited by 159
Metushi, I. G., Hayes, M. A., & Uetrecht, J. (2015) · Hepatology · doi:10.1002/hep.27549 · Cited by 158 · cited 7×
“CTLA4 binds with CD80 or CD86 on the membrane of APC, acting as inhibitory signal.”
InfluentialImmunotherapy for Hepatocellular Carcinoma: A 2021 Update
Kole, C., Charalampakis, N., Tsakatikas, S. A., Vailas, M. G., Moris, D., Gkotsis, E., Kykalos, S., Karamouzis, M. V., & Schizas, D. (2020) · Cancers · doi:10.3390/cancers12102859 · Cited by 149 · cited 4×
“Conversely, rats are more resistant to APAP damage, possibly due to a higher scavenger enzyme activity and thus to reduced oxidative stress [110].”
BackgroundInfluentialComprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry
Stephens, C., Robles-Diaz, M., Medina-Caliz, I., Garcia-Cortes, M., Ortega-Alonso, A., Sanabria-Cabrera, J., Gonzalez-Jimenez, A., Alvarez-Alvarez, I., Slim, M., Jimenez-Perez, M., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.029 · Cited by 148 · cited 1×
“Registries such as the Spanish DILI Registry represent invaluable tools to study the epidemiology and disease course of DILI [2].”
MethodSelf-citationSafety data and withdrawal of hepatotoxic drugs
Babai, S., Auclert, L., & Le-Louët, H. (2018) · Therapies · doi:10.1016/j.therap.2018.02.004 · Cited by 137 · cited 1×
“Since DILI represents the major cause of medications withdrawal from the market [111] and of acute liver failure events around the world [112], the development of methods possibly revealing hepatotoxic effects of drug candidates during the first phases of production are of paramount importance.”
BackgroundA missense variant in PTPN22 is a risk factor for drug-induced liver injury
Cirulli, E. T., Nicoletti, P., Abramson, K., Andrade, R. J., Bjornsson, E. S., Chalasani, N., Fontana, R. J., Hallberg, P., Li, Y. J., Lucena, M. I., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.034 · Cited by 137 · cited 10×
“Vang and colleagues have suggested that the PTPN22 R620W is a switch-of-function polymorphism which can operate as both a gain-of-function and a loss-of-function variant [14].”
BackgroundInfluentialSelf-citationToward Predictive Models for Drug-Induced Liver Injury in Humans: Are we There Yet?
Chen, M., Bisgin, H., Tong, L., Hong, H., Fang, H., Borlak, J., & Tong, W. (2014) · Biomarkers in Medicine · doi:10.2217/bmm.13.146 · Cited by 136 · cited 4×
“Yet, the predictive power of this model is not as effective as envisioned; the alteration in the gene expression is not necessarily relevant and associated to DILI [113].”
BackgroundInfluentialBuchweitz, J. P., Ganey, P. E., Bursian, S. J., & Roth, R. A. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.2.460 · Cited by 134
Models of Drug Induced Liver Injury (DILI)—Current Issues and Future Perspectives
Kuna, L., Bozic, I., Kizivat, T., Bojanic, K., Mrso, M., Kralj, E., Smolic, R., Wu, G. Y., & Smolic, M. (2018) · Current Drug Metabolism · doi:10.2174/1389200219666180523095355 · Cited by 127 · cited 3×
“To conclude, current in vitro and in vivo model systems are still not adequate enough to understand the pathogenic mechanisms of this complex condition, particularly for the idiosyncratic type [118].”
BackgroundInfluentialDrug-Induced Liver Injury with Autoimmune Features
Foureau, D., Jacobs, C., Ahrens, W., Russo, M., Bonkovsky, H., & deLemos, A. (2014) · Seminars in Liver Disease · doi:10.1055/s-0034-1375959 · Cited by 126 · cited 1×
“Finally, hypergammaglobulinemia and circulating autoantibodies (against CYP2E1 or liver endoplasmic reticulum proteins, among others), and liver infiltrating plasma cells are found in DILI with autoimmune features (AI-DILI), that can be induced by α-methyl DOPA, hydralazine, isoniazide, and other compounds [79,80].”
BackgroundT cell recognition of penicillin G: Structural features determining antigenic specificity
Padovan, E., Mauri-Hellweg, D., Pichler, W. J., & Weltzien, H. U. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260107 · Cited by 123 · cited 3×
“A well-known example of the “hapten” concept is the penicillin covalent binding to lysin residues, leading to presentation of penicilloyl peptides in the context of HLA to drug-specific T cells [69,71,72].”
BackgroundInnate Immune Cell Trafficking and Function During Sterile Inflammation of the Liver
McDonald, B., & Kubes, P. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.09.048 · Cited by 123 · cited 1×
“Indeed, innate immunity can be activated by damage-associated molecular patterns (DAMPs) released by drug-injured hepatocytes, resulting in inflammation in the absence of infectious agents, so-called sterile inflammation [16,17] (for definition of DAMPs and a brief outline on inflammation, see Box 1).”
BackgroundTolosa, L., Pinto, S., Donato, M. T., Lahoz, A., Castell, J. V., O’Connor, J. E., & Gómez-Lechón, M. J. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfs083 · Cited by 121 · cited 1×
“To overcome this limitation, one can use a panel of characterized assays in parallel, studying simultaneously multiple endpoints in live cells: to name the most important ones, steatosis, ROS production, phospholipidosis, mitochondria membrane integrity, oxidative stress, intracellular calcium homeostasis, inhibition…”
BackgroundPolarized expression of drug transporters in differentiated human hepatoma HepaRG cells
Vée, M. L., Noel, G. L., Jouan, E., Stieger, B., & Fardel, O. (2013) · Toxicology in Vitro · doi:10.1016/j.tiv.2013.07.003 · Cited by 120 · cited 1×
“HepaRG can proliferate and differentiate to form colonies surrounded by epithelial cells expressing metabolizing enzymes and drug transporters [127,128].”
BackgroundHuman biomimetic liver microphysiology systems in drug development and precision medicine
Gough, A., Soto-Gutierrez, A., Vernetti, L., Ebrahimkhani, M. R., Stern, A. M., & Taylor, D. L. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00386-1 · Cited by 117 · cited 1×
“) has to be used for the development of increasingly efficient “3D microphysiology systems” (miniaturized functional liver units constructed with multiple cell types under a variety of mechanical and biochemical cues) for the study of DILI [116,147,148].”
BackgroundVinci, B., Duret, C., Klieber, S., Gerbal‐Chaloin, S., Sa‐Cunha, A., Laporte, S., Suc, B., Maurel, P., Ahluwalia, A., & Daujat‐Chavanieu, M. (2011) · Biotechnology Journal · doi:10.1002/biot.201000326 · Cited by 116 · cited 1×
“An important caveat is that vascular structures and cholangiocytes cannot be generated in the 3D spheroids and the model does not include a physiological blood flow, which hampers both detoxification capacity and oxygen and chemical gradients [124,144].”
BackgroundMechanisms of Inflammatory Liver Injury and Drug-Induced Hepatotoxicity
Woolbright, B. L., & Jaeschke, H. (2018) · Current Pharmacology Reports · doi:10.1007/s40495-018-0147-0 · Cited by 104 · cited 1×
“Different mechanisms can underly AI-DILI, for example breaking of immune tolerance due to drug-induced cell damage with DAMP release, the formation of drug-protein adducts that stimulate innate immunity, which in turn activates adaptive responses against self-antigens [81].”
BackgroundFoureau, D. M., Walling, T. L., Maddukuri, V, Anderson, W., Culbreath, K., Kleiner, D. E., Ahrens, W. A., Jacobs, C., Watkins, P. B., Fontana, R. J., et al. (2015) · Clinical and Experimental Immunology · doi:10.1111/cei.12558 · Cited by 101 · cited 3×
“Neutrophils are a major component of liver infiltrate in DILI, as demonstrated by immunohistochemistry studies on liver biopsies [24].”
BackgroundZhao, S., Jiang, J., Jing, Y., Liu, W., Yang, X., Hou, X., Gao, L., & Wei, L. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2264-z · Cited by 101 · cited 1×
“It seems that low TNF-α concentrations promote proliferation, while high concentrations cause cell death, paving the way for new therapeutic approaches to DILI [38].”
BackgroundAntoniades, C. G., Khamri, W., Abeles, R. D., Taams, L. S., Triantafyllou, E., Possamai, L. A., Bernsmeier, C., Mitry, R. R., O'Brien, A., Gilroy, D., et al. (2014) · Hepatology · doi:10.1002/hep.26933 · Cited by 99
Zhang, C., Feng, J., Du, J., Zhuo, Z., Yang, S., Zhang, W., Wang, W., Zhang, S., Iwakura, Y., Meng, G., et al. (2018) · Cellular & Molecular Immunology · doi:10.1038/cmi.2017.22 · Cited by 99 · cited 1×
“), and amplifies the inflammatory process by activating infiltrating leukocytes [31].”
BackgroundKim, S., Saide, K., Farrell, J., Faulkner, L., Tailor, A., Ogese, M., Daly, A. K., Pirmohamed, M., Park, B. K., & Naisbitt, D. J. (2015) · Hepatology · doi:10.1002/hep.27912 · Cited by 98 · cited 7×
“The proposed scheme of T-cell priming is in agreement with in vitro experiments showing enhanced T-cell priming to nitroso-sulfamethoxazole, a sulfamethoxazole derivative, after exposure of monocyte-derived DCs to HMGB1 isoform A, one of the most investigated DAMPs [61].”
BackgroundResultInfluentialChiu, H.-J., Gardner, C. R., Dambach, D. M., Durham, S. K., Brittingham, J. A., Laskin, J. D., & Laskin, D. L. (2003) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2003.07.003 · Cited by 98 · cited 5×
“For example, neutrophil depletion by anti-Ly6G antibody treatment resulted in reduced hepatocyte proliferation and increased liver necrosis in mouse APAP-DILI [55].”
BackgroundInfluentialInfiltrating monocytes in liver injury and repair
Brempelis, K. J., & Crispe, I. N. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.62 · Cited by 97 · cited 12×
“Recruitment and activation of effector T cells into the liver can result in liver damage via different mechanisms, including production of diverse proinflammatory (IFN-γ, IL-17, etc.) and pro-allergic (IL-4, IL-5, IL-13, etc.) cytokines by CD4+ T cells, and cytotoxicity via either exocytosis of perforin- and granzyme-…”
BackgroundInfluentialCell death in drug-induced liver injury
Iorga, A., & Dara, L. (2019) · Advances in Pharmacology · doi:10.1016/bs.apha.2019.01.006 · Cited by 88
Martin-Murphy, B. V., Kominsky, D. J., Orlicky, D. J., Donohue, T. M., & Ju, C. (2013) · Hepatology · doi:10.1002/hep.26134 · Cited by 84 · cited 1×
“In contrast, another study showed exacerbated liver damage in both Jα18−/− and CD1d−/− mice after starvation, and this was associated with CYP2E1 up-regulation and enhanced formation of hepatic APAP-protein adducts, suggesting a protective role of iNKT cells [48].”
ResultAcquired mechanisms of immune escape in cancer following immunotherapy
Iorgulescu, J. B., Braun, D. A., Oliveira, G., Keskin, D. B., & Wu, C. J. (2018) · Genome Medicine · doi:10.1186/s13073-018-0598-2 · Cited by 82 · cited 1×
“Cancer evolution has brought some tumors to develop the ability to produce these molecules as a mechanism to escape from immune system control [104].”
BackgroundPolygenic architecture informs potential vulnerability to drug-induced liver injury
Koido, M., Kawakami, E., Fukumura, J., Noguchi, Y., Ohori, M., Nio, Y., Nicoletti, P., Aithal, G. P., Daly, A. K., Watkins, P. B., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1023-0 · Cited by 82 · cited 2×
“involved in mitochondria and translation in subjects with higher PRS values and pointed out that DILI susceptibility is due to several biological pathways in hepatocytes, including oxidative stress and unfolded protein response [15].”
BackgroundBiomarkers of drug-induced liver injury
McGill, M. R., & Jaeschke, H. (2019) · Advances in Pharmacology · doi:10.1016/bs.apha.2019.02.001 · Cited by 78 · cited 1×
“DAMPs, such as high mobility group box-1 (HMGB1), keratin 18 (K18), and adenosine triphosphate (ATP), are currently studied as promising DILI biomarkers and therapeutic targets; this is the case for Acetaminophen (APAP) overdose, a very common cause of DILI in Western countries [23].”
BackgroundMak, A., & Uetrecht, J. (2015) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00305 · Cited by 76
Lee, K., Kang, M., Lee, Y. S., Kim, Y., Kim, D., Ko, H., & Kang, C. (2008) · Cellular Immunology · doi:10.1016/j.cellimm.2008.03.004 · Cited by 74
Lu, J., Jones, A. D., Harkema, J. R., Roth, R. A., & Ganey, P. E. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfr266 · Cited by 73
Wuillemin, N., Terracciano, L., Beltraminelli, H., Schlapbach, C., Fontana, S., Krähenbühl, S., Pichler, W. J., & Yerly, D. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.02.018 · Cited by 72 · cited 2×
“The fact that individuals carrying certain HLA alleles have increased risk to develop DILI when treated with particular drugs can be explained by the preferential molecular association of the drug and/or its metabolites with certain peptide carrying-HLA alleles, for example flucloxacillin, also known as floxacillin, w…”
BackgroundWu, Y., Geng, X., Wang, J., Miao, Y., Lu, Y., & Li, B. (2016) · Cell Biology and Toxicology · doi:10.1007/s10565-016-9316-2 · Cited by 72 · cited 1×
“), HepaRG is a promising predictive in vitro model and it is composed by a mixture of biliary-like cells and hepatocytes [125,126].”
BackgroundWatkins, S., & Pichler, W. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076211 · Cited by 71
Agostinetto, E., Eiger, D., Lambertini, M., Ceppi, M., Bruzzone, M., Ponde, N. F., Plummer, C., Awada, A. H., Santoro, A., Piccart, M. J., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.043 · Cited by 70 · cited 1×
“Due to their mechanism of action, ICI-related adverse events (AEs) are mostly immune-related AEs, and can affect any organ [97].”
BackgroundSelf-citationHoffmann, S. A., Müller‐Vieira, U., Biemel, K., Knobeloch, D., Heydel, S., Lübberstedt, M., Nüssler, A. K., Andersson, T. B., Gerlach, J. C., & Zeilinger, K. (2012) · Biotechnology and Bioengineering · doi:10.1002/bit.24573 · Cited by 69 · cited 1×
“In some cases, even vascular- and bile canaliculi-like structures have been observed [145,146].”
BackgroundInvolvement of Toll-like receptor 4 in acetaminophen hepatotoxicity
Yohe, H. C., O'Hara, K. A., Hunt, J. A., Kitzmiller, T. J., Wood, S. G., Bement, J. L., Bement, W. J., Szakacs, J. G., Wrighton, S. A., Jacobs, J. M., et al. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00239.2005 · Cited by 69 · cited 1×
“It must be noted, however, that there are also differences among mice strains, mostly due to the presence of spontaneous mutations or polymorphisms in the genome that affect either the antioxidant capacity or their ability to respond to endotoxins [150,151].”
BackgroundYi, F., Liu, G.-H., & Belmonte, J. C. I. (2012) · Protein & Cell · doi:10.1007/s13238-012-2918-4 · Cited by 69 · cited 1×
“The use of human induced pluripotent stem cell for derivation of hepatocyte-like cells represents another option despite remaining suboptimal, because cells are not fully metabolically competent and show very low levels of activity of the metabolizing enzymes [129,130].”
BackgroundMechanisms Balancing Tolerance and Immunity in the Liver
Böttcher, J. P., Knolle, P. A., & Stabenow, D. (2011) · Digestive Diseases · doi:10.1159/000329801 · Cited by 64 · cited 1×
“All liver cells express MHC-I molecules and can become targets of cytotoxic CD8+ T cells, while normally only a few cells of hematopoietic origin express MHC-II molecules, such as hepatic DCs [67].”
BackgroundGudd, C. L. C., Au, L., Triantafyllou, E., Shum, B., Liu, T., Nathwani, R., Kumar, N., Mukherjee, S., Dhar, A., Woollard, K. J., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.02.008 · Cited by 64 · cited 1×
“These peripheral phenomena are reflected by liver inflammation dominated by co-localised CD8+ lymphocytes and CCR2+ macrophages [107].”
BackgroundParham, L. R., Briley, L. P., Li, L., Shen, J., Newcombe, P. J., King, K. S., Slater, A. J., Dilthey, A., Iqbal, Z., McVean, G., et al. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2015.40 · Cited by 63 · cited 1×
“Previous studies had identified examples of HLA alleles associated with structurally different compounds, such as DRB1*15:01 with amoxicillin-clavulanate and lumiracoxib and DRB1*07:01 with lapatinib and ximelagatran [11].”
ResultAntigen presentation by liver sinusoidal lining cells after antigen exposure in vivo.
Rubinstein, D., Roska, A. K., & Lipsky, P. E. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.5.1377 · Cited by 63 · cited 1×
“It remains to be determined whether cells other than liver DCs play a role in T cell priming in DILI, for example LN macrophages, or liver KCs, and endothelial cells, as shown in other conditions [64,65].”
BackgroundProtective effect of Th22 cells and intrahepatic IL-22 in drug induced hepatocellular injury
Lai, R., Xiang, X., Mo, R., Bao, R., Wang, P., Guo, S., Zhao, G., Gui, H., Wang, H., Bao, S., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.004 · Cited by 63
Mak, A., & Uetrecht, J. (2015) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00137 · Cited by 61 · cited 2×
“, reported that mice with a reduced level of Sod2 developed mild liver injury after administration of troglitazone [161], but these data were not further confirmed and, on the contrary, experiments performed in PD1−/− anti-CTLA4-treated mice do not seem to support such an important role of mitochondrial damage in iDIL…”
BackgroundWeber, S., Benesic, A., Rotter, I., & Gerbes, A. L. (2019) · Liver International · doi:10.1111/liv.14195 · Cited by 53 · cited 9×
“Other hallmarks of AIH seem to be missing too, like autoantibodies or IgG elevations [106], even though evidence is still scarce and conflicting, with reports of about 50% of patients positive to ANA antibodies [106].”
MethodInfluentialCruz‐Monteagudo, M., Borges, F., Cordeiro, M. N. D. S., Fajín, J. L. C., Morell, C., Molina, R., Cañizares-Carmenate, Y., & Domínguez, E. R. (2008) · Journal of Combinatorial Chemistry · doi:10.1021/cc800115y · Cited by 52
Duan, L., Davis, J. S., Woolbright, B. L., Du, K., Cahkraborty, M., Weemhoff, J. L., Jaeschke, H., & Bourdi, M. (2016) · Food and Chemical Toxicology · doi:10.1016/j.fct.2016.10.021 · Cited by 51 · cited 1×
“It must be noted, however, that there are also differences among mice strains, mostly due to the presence of spontaneous mutations or polymorphisms in the genome that affect either the antioxidant capacity or their ability to respond to endotoxins [150,151].”
BackgroundFraser, K., Bruckner, D. M., & Dordick, J. S. (2018) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.8b00054 · Cited by 50 · cited 1×
“Overall, a valid predictive model should integrate chemical structure, cellular endpoints, multiple data sources and toxicogenomics data [113,123].”
BackgroundInvolvement of natural killer T cells in halothane-induced liver injury in mice
Cheng, L., You, Q., Yin, H., Holt, M. R., & Ju, C. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.03.025 · Cited by 48 · cited 1×
“For example, in halothane-DILI, a pro-inflammatory role of iNKT cells has been suggested, as a greatly reduced neutrophil infiltration was observed in CD1d−/− mice [45].”
BackgroundMultiparametric assay using HepaRG cells for predicting drug-induced liver injury
貴文, 富., Okamura, H., Satsukawa, M., Yokoi, T., & Konno, Y. (2015) · Toxicology Letters · doi:10.1016/j.toxlet.2015.04.014 · Cited by 41 · cited 1×
“), HepaRG is a promising predictive in vitro model and it is composed by a mixture of biliary-like cells and hepatocytes [125,126].”
BackgroundBachmann, M., Pfeilschifter, J. M., & Mühl, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00161 · Cited by 41
Characterization of Drug-Specific Signaling Between Primary Human Hepatocytes and Immune Cells
Ogese, M. O., Faulkner, L., Jenkins, R. E., French, N. S., Copple, I. M., Antoine, D. J., Elmasry, M., Malik, H., Goldring, C. E., Park, B. K., et al. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx069 · Cited by 38
Stem-cell derived hepatocyte-like cells for the assessment of drug-induced liver injury
Donato, M. T., & Tolosa, L. (2019) · Differentiation · doi:10.1016/j.diff.2019.02.004 · Cited by 36 · cited 1×
“Some potential improvements of this model have been proposed [131].”
BackgroundContribution of Non-parenchymal Cells to the Performance of Micropatterned Hepatocytes
Zinchenko, Y. S., Culberson, C. R., & Coger, R. N. (2006) · Tissue Engineering · doi:10.1089/ten.2006.12.2241 · Cited by 34
Genetic Predisposition to Drug-Induced Liver Injury
Stephens, C. M., & Andrade, R. J. (2019) · Clinics in Liver Disease · doi:10.1016/j.cld.2019.08.003 · Cited by 34 · cited 3×
“Regarding GWAS related to iDILI, most of them have examined the genetic predisposition to a single specific drug or class, whereas more recent studies have revealed some risk variants related to general predisposition independent of drug type [1,9,10].”
BackgroundSelf-citationThe complexity of T cell–mediated penicillin hypersensitivity reactions
Goh, S. J. R., Tuomisto, J. E. E., Purcell, A. W., Mifsud, N. A., & Illing, P. T. (2020) · Allergy · doi:10.1111/all.14355 · Cited by 33 · cited 1×
“A well-known example of the “hapten” concept is the penicillin covalent binding to lysin residues, leading to presentation of penicilloyl peptides in the context of HLA to drug-specific T cells [69,71,72].”
BackgroundTailor, A., Meng, X., Adair, K., Farrell, J., Waddington, J. C., Daly, A. K., Pirmohamed, M., Dear, G. J., Park, B. K., & Naisbitt, D. J. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa128 · Cited by 29
Knockdown of superoxide dismutase 2 enhances acetaminophen-induced hepatotoxicity in rat
Yoshikawa, Y., Morita, M., Hosomi, H., Tsuneyama, K., Fukami, T., Nakajima, M., & Yokoi, T. (2009) · Toxicology · doi:10.1016/j.tox.2009.07.017 · Cited by 27 · cited 1×
“reduction of anti-oxidant capacity, either through a reduction in GSH production [110] or in SOD activity [149].”
BackgroundCho, T., Wang, X., Yeung, K., Cao, Y., & Uetrecht, J. (2021) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.0c00485 · Cited by 25
Downs, I., Aw, T. Y., Liu, J., Adegboyega, P. A., & Ajuebor, M. N. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.10.029 · Cited by 24 · cited 1×
“Similarly, in APAP-DILI, intrahepatic iNKT cell reduction or loss were associated to either ameliorated disease after treatment with glycosphingolipids and/or vitamin E [46], or increased glutathione levels and enhanced NAPQI (an APAP reactive metabolite) detoxification [47].”
BackgroundPresentations, Causes and Outcomes of Drug-Induced Liver Injury in Egypt
Alhaddad, O., Elsabaawy, M., Abdelsameea, E., Abdallah, A., Shabaan, A., Ehsan, N., Elrefaey, A., Elsabaawy, D., & Salama, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-61872-9 · Cited by 23
Critical role of CXC chemokines in endotoxemic liver injury in mice
Jaeschke, H., & Bajt, M. L. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0504309 · Cited by 19 · cited 1×
“β2 integrin-mediated interactions are also required for neutrophil/hepatocyte contact, that leads to the production of reactive oxygen species (ROS) by neutrophils, and hepatocytes damage and death [49,50].”
BackgroundRosa, F. D., Serafini, B., Scognamiglio, P., Virgilio, A. D., Finocchi, L., Aloisi, F., & Barnaba, V. (2000) · International Immunology · doi:10.1093/intimm/12.5.711 · Cited by 18 · cited 1×
“The autoimmune reaction is usually self-limited, and disease resolves after drug withdrawal [1,82].”
BackgroundTolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury
Gibson, A., Hammond, S., Jaruthamsophon, K., Roth, S. E., Mosedale, M., & Naisbitt, D. J. (2020) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.0c00328 · Cited by 17 · cited 1×
“Another example of drug-elicited T cell-effector function is the production of IFN-γ, IL-13, and granzyme B by CD4+ T cells from patients with tolvaptan-induced DILI [76].”
BackgroundMizrahi, M., Adar, T., Lalazar, G., Nachman, D., El-Haj, M., Yaʼacov, A. B., Lichtenstein, Y., Shabat, Y., Kanovich, D., Zolotarov, L., et al. (2018) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00071 · Cited by 16 · cited 1×
“Similarly, in APAP-DILI, intrahepatic iNKT cell reduction or loss were associated to either ameliorated disease after treatment with glycosphingolipids and/or vitamin E [46], or increased glutathione levels and enhanced NAPQI (an APAP reactive metabolite) detoxification [47].”
BackgroundCottagiri, M., Nyandjo, M., Stephens, M., Mantilla, J. J., Saito, H., Mackay, I. R., Rose, N. R., & Njoku, D. B. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0087-y · Cited by 15
Zhao, J., Kim, J.-W., Zhou, Z., Qi, J., Tian, W., Lim, C. W., Han, K. M., & Kim, B. (2020) · Molecular Pharmacology · doi:10.1124/molpharm.120.000043 · Cited by 15 · cited 1×
“Neutropenia induced by the use of anti-neutrophil antibodies before APAP overdose can reduce hepatotoxicity [152], but an important role seems also to be played by Kupffer cell activation, since a depletion of this liver component significantly reduced liver damage in APAP overdose in mice [153].”
BackgroundHanafusa, H., Morikawa, Y., Uehara, T., Kaneto, M., Ono, A., Yamada, H., Ohno, Y., & Urushidani, T. (2014) · Toxicology · doi:10.1016/j.tox.2014.07.005 · Cited by 13 · cited 1×
“They can get recruited by increased chemokines into the liver [66], wherein they can be triggered upon recognition of drug-modified-peptide-HLA complexes on the surface of different types of liver cells (Figure 1D).”
BackgroundA switch-variant model integrates the functions of an autoimmune variant of the phosphatase PTPN22
Vang, T., Nielsen, J., & Burn, G. L. (2018) · Science Signaling · doi:10.1126/scisignal.aat0936 · Cited by 12 · cited 4×
“There is evidence that the rs2476601 SNP is associated with increased genesis of autoreactive B cell receptors, inhibition of T-cell receptor signaling and modification of T-cell adhesion [14].”
BackgroundInfluentialOpen challenges in the management of autoimmune hepatitis
Gerussi, A., Halliday, N., Carbone, M., Invernizzi, P., & Thorburn, D. (2020) · Minerva Gastroenterology · doi:10.23736/s1121-421x.20.02805-6 · Cited by 5 · cited 1×
“Plasma cell infiltrates are not typical of ICI-induced hepatitis [106,108], in contrast to classical AIH, where they constitute the predominant cell type together with lymphocytes and accumulate in periportal areas [109].”
ResultSelf-citation
Cited by
Drug induced liver injury – a 2023 update
Allison, R., Guraka, A., Shawa, I. T., Tripathi, G., Moritz, W., & Kermanizadeh, A. (2023) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937404.2023.2261848 · Cited by 167
“In contrast to the original peptide, these altered peptides may have altered MHC molecule binding affinities (Adair, Meng, and Naisbitt 2021; Gerussi et al. 2021; Pichler 2013).”
BackgroundInfluentialPreclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction
Segovia-Zafra, A., Di Zeo-Sánchez, D. E., López-Gómez, C., Pérez-Valdés, Z., García-Fuentes, E., Andrade, R. J., Lucena, M. I., & Villanueva-Paz, M. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.013 · Cited by 70
Self-citationChallenges and Future of Drug-Induced Liver Injury Research—Laboratory Tests
Weber, S., & Gerbes, A. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116049 · Cited by 67
“However, PHHs show high phenotypic variability and instability regarding phenotypic characteristics in in vitro cultures, while liver cell lines are derived from liver cancer cells and therefore lack physiological drug-metabolizing enzymes and transporters limiting the representativeness of normal cellular toxic respo…”
BackgroundMechanisms of drug induced liver injury
Skat‐Rørdam, J., Lykkesfeldt, J., Gluud, L. L., & Tveden‐Nyborg, P. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05744-3 · Cited by 69
“This is in contrast to amoxicillin-clavulanate DILI where immune activation is generally believed to be a dete-riorative response further aggravating cell death [ 113 ].”
Endoplasmic Reticulum Stress and Mitochondrial Stress in Drug-Induced Liver Injury
Pu, S., Pan, Y., Zhang, Q., You, T., Yue, T., Zhang, Y., & Wang, M. (2023) · Molecules · doi:10.3390/molecules28073160 · Cited by 63
Metadata
- Authors
- Gerussi, A., Natalini, A., Antonangeli, F., Mancuso, C., Agostinetto, E., Barisani, D., Di Rosa, F., Andrade, R., & Invernizzi, P.
- Affiliations
- Azienda Ospedaliera San Gerardo (IT)
- Institute of Molecular Biology and Pathology (IT)
- Université Libre de Bruxelles (BE)
- Institute of Molecular Biology and Pathology (IBPM), National Research Council of Italy (CNR), 00185 Rome, Italy
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), UGC Aparato Digestivo, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, 29016 Málaga, Spain
- Corresponding author
- Gerussi, Alessio
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-04-27
- Volume
- 22
- Issue
- 9
- Pages
- 4557
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8123708
- OpenAlex
- W3159227089
- Cited by
- 87
- References
- 168
- Citations by year
- 2026: 19 · 2025: 21 · 2024: 15 · 2023: 16 · 2022: 12 · 2021: 4
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by)
- BOA (University of Milano-Bicocca) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministero dell’Istruzione, dell’Università e della Ricerca
- American Medical Association Foundation
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Keywords
- drug-induced liver injury, immunogenetics, genetic susceptibility, autoimmune hepatitis, immune-mediated liver injury, pathogenesis, animal models
- MeSH terms
- Humans, Immunogenetics, Liver, Models, Theoretical, Phenotype, Risk Factors, Hepatitis, Autoimmune, Genetic Predisposition to Disease, Chemical and Drug Induced Liver Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
